| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Innoviva Specialty Therapeutics commercial momentum continues with $43.3 million generated in U.S. net product sales, representing 45% year-over-year growth |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
IST achieved U.S. net product sales of $36.6 million in the second quarter, representing 26% year-over-year growth |
| 18 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
Generated $58.6 million in revenue from resilient royalties portfolio |
| 04 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At the Annual Meeting of Stockholders held on May 4, 2026 (the “Meeting”), the stockholders of Innoviva, Inc. (“Innoviva”) elected five members to our board of directors, each for a one-year term expiring at the annual meeting of stockho... |
| 25 Feb 2026 |
8-K: Results of Operations and Financial Condition
Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Generated $63.4 million in revenue from durable royalties portfolio |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
Strong royalties portfolio performance with $67.3 million in revenue |
| 21 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
At the Annual Meeting of Stockholders held on May 19, 2025 (the “Meeting”), the stockholders of Innoviva, Inc. (“Innoviva”) elected five members to our board of directors, each for a one-year term expiring at the annual meeting of stockh... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
Core royalty platform maintained strong performance, generating $61.3 million in revenue |
| 26 Feb 2025 |
8-K: Results of Operations and Financial Condition
Core royalty platform continues to deliver with GSK royalties of $66.0 million for the fourth quarter and $255.6 million for the full year |
| 06 Nov 2024 |
8-K: Results of Operations and Financial Condition
Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth |
| 31 Jul 2024 |
8-K: Results of Operations and Financial Condition
Core royalty platform continued strong performance, receiving GSK royalties of $67.2 million |
| 20 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
At the Annual Meeting of Stockholders held on June 17, 2024 (the “Meeting”), the stockholders of Innoviva, Inc. (“Innoviva”) elected six members to our board of directors, each for a one-year term expiring at the annual meeting of stockh... |
| 13 May 2024 |
8-K: Regulation FD Disclosure
Forward - looking statements The information in this presentation contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as... |
| 08 May 2024 |
8-K: Results of Operations and Financial Condition
Core royalty platform on track; receiving GSK royalties of $61.9 million |
| 30 Apr 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers |
| 29 Feb 2024 |
8-K: Results of Operations and Financial Condition
Core royalty platform on track; received GSK royalties of $69.6 million for fourth quarter |
| 06 Nov 2023 |
8-K: Regulation FD Disclosure
Zoliflodacin Phase 3 clinical trial topline data November 2, 2023 |
| 01 Nov 2023 |
8-K: Results of Operations and Financial Condition
Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023 |
Loading...